

MDM4 genetic variants predict HPV16-positive tumors of patients with squamous cell carcinoma of the oropharynx

Zhongming Lu^{1,2,3,*}, Hua Zhang^{2,4,*}, Ye Tao^{2,5}, Xiangping Li¹ and Guojun Li^{2,6}

¹Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

²Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

³Department of Otolaryngology-Head and Neck Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China

⁴Department of Otolaryngology-Head and Neck Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China

⁵Department of Otolaryngology-Head and Neck Surgery, The 2nd Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, China

⁶Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

*These authors have contributed equally to this work

Correspondence to: Xiangping Li, **email:** li321162@qq.com
Guojun Li, **email:** gli@mdanderson.org

Keywords: MDM4 polymorphism, genetic susceptibility, HPV, SCCOP, biomarkers

Received: March 13, 2017

Accepted: August 30, 2017

Published: September 30, 2017

Copyright: Lu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The increasing incidence of squamous cell carcinoma of the oropharynx (SCCOP) is majorly attributed to the human papillomavirus (HPV) infection. Both HPV and MDM4 play a critical role in inhibition of p53 activity, thus affecting HPV tumor status of SCCOP. Three polymorphisms in *MDM4* were genotyped from blood genomic DNA samples and HPV16 status in tumor specimens was examined. Odds ratio (OR) and 95% confidence intervals (CIs) in univariate and multivariable logistic regression models were calculated for the associations between these polymorphisms and HPV16 status. Three *MDM4* variant genotypes were significantly associated with HPV16 tumor status among SCCOP patients compared with the common homozygous genotypes (OR, 0.6; 95% CI, 0.4–1.0 for rs10900598; OR, 1.6, 95% CI; 1.1–2.4 for rs1380576; and OR, 1.8, 95% CI, 1.1–2.9 for rs11801299; respectively). When we combined all risk genotypes of the 3 polymorphisms, the patients carrying 1-3 *MDM4* risk genotypes were approximately 2.5 time as likely to have an HPV16-positive tumor than those with no risk genotypes (OR, 2.5, 95% CI, 1.6–3.9). Additionally, modifying effect of *MDM4* risk genotypes was more pronounced among non-Hispanic white, never-smokers, and never-drinkers. Potential functional polymorphisms in *MDM4* may serve as biomarkers for predicting tumor HPV16 status among SCCOP patients, particularly in non-Hispanic white, never-smokers and never-drinkers. However, validation of these results in larger studies is needed.

INTRODUCTION

Historically, the majority of SCCHN are contributed to tobacco and alcohol use. However, Squamous

cell carcinoma of the oropharynx (SCCOP), one of subgroups of SCC of head and neck (SCCHN), has recently become one of the only five cancer types that are growing significantly in incidence regardless of the

Table 1: Demographic characteristics of SCCOP patients by HPV16 status

Variable	HPV16 ⁺ patients (N =439)		HPV16 ⁻ patients (N =113)		P value*
	No.	%	No.	%	
Age					0.856
≤54 years	225	51.2	59	52.2	
>54 years	214	48.8	54	47.8	
Sex					0.0012
Male	384	87.5	85	75.2	
Female	55	12.5	28	24.8	
Ethnicity					0.141
Non-Hispanic white	404	92.0	99	87.6	
Others	35	8.0	14	12.4	
Tobacco smoking					0.050
Ever	252	57.4	76	67.0	
Never	187	42.6	37	33.0	
Alcohol drinking					0.483
Ever	331	75.4	88	78.6	
Never	108	24.6	25	21.4	

*Two-sided χ^2 test.

decline in smoking rate in the United States [1]. Human papillomavirus (HPV) infection has been well established as the principal cause for the increased incidence of SCCOP [1–7]. Among over 150 known HPV subtypes, the HPV 16 is the most common subtype for SCCOP and accounts for up to 95% of HPV-positive cases [8]. HPV16-positive SCCOP has been widely recognized to be a distinct disease and has better treatment outcome compared with HPV16-negative SCCOP [9, 10]. Besides HPV infection, as a necessary but not a sufficient cause of SCCOP, other factors, such as genetic factors, may also be necessary in malignant transformation of HPV infected cells.

Mouse double minute 4 (MDM4 or MDMX) is a homolog of MDM2, a key gene for negatively regulating p53, and its expression alterations may contribute to cancer development through p53 inhibition. p53 has been regarded as “the guardian of the genome” [11] and genetic alterations in the p53-dependent pathway play a crucial role in regulating expression of various genes in many cancers including SCCOP [12]. It has been revealed that MDM4 exerts its oncogenic activity by binding to the p53 transactivation domain, leading to inhibition of its transcriptional activity along with MDM2 oncoprotein [13]. Previous study suggested that functional single nucleotide polymorphisms (SNPs) of these p53-related genes, including *MDM4* and *MDM2*, could predict the risk

of HPV-associated SCCOP [14]. HPV E6 protein, a major HPV oncogenic protein [15], activates telomerase and binds p53 for degradation via the ubiquitination, leading to protein dysfunction, degradation, and loss of cell cycle control through an ubiquitin-dependent pathway [16]. However, only a very small proportion of HPV-infected individuals ultimately develop HPV-positive SCCOP [17], indicating that other genetic variations may also be attributed to HPV tumor status of SCCOP.

Given the distinct roles of HPV E6 and MDM4 in regulation of p53, with a direct degradation of p53 by HPV E6 and an inhibition of p53 transcription by MDM4, both leading to downexpression of p53, the possible link in mechanisms on p53 downregulation by HPV E6 and MDM4 is less investigated. The degradation of Rb by E7 releases the E2F transcription factors, resulting in the uncontrolled cell cycle and cell proliferation [18]. The released E2F will activate the p14 transcription and lead to the dissociation of p53 from MDM2, a homolog of MDM4, inducing p53-dependent apoptosis [18]. Thus, MDM4 may have a similar effect on p53 activity through its link with HPV, while this hypothesis warrants further future investigation. Some studies have indicated the development of SCCOP associated with HPV16 may be affected by *MDM4* genetic variants [18], while whether *MDM4* variants are associated with tumor HPV16 status in SCCOP patients remains unknown. Thus, given the role

of HPV16 status as a biomarker for predicting prognosis of SCCOP, we evaluated whether *MDM4* polymorphisms could be served as a susceptibility biomarker for HPV16 tumor status in SCCOP patients.

RESULTS

The distribution of 552 SCCOP patients' demographic characteristics as well as smoking and alcohol history is summarized in Table 1. Among these 552 patients with SCCOP, 439 (79.5%) were positive and 113 (20.5%) were negative for tumor HPV16 DNA. HPV16-positive patients have higher possibility of man and never-smokers than HPV16-negative patients ($P = 0.0012$ for sex and $P = 0.050$ for smoking status, respectively). Additionally they were more likely to be non-Hispanic white and never drinkers, but the statistical difference were not significantly different ($P = 0.141$ for race and $P = 0.483$ for alcohol status, respectively).

Table 2 shows the genotype distribution of these 3 *MDM4* polymorphisms, rs10900598, rs1380576, and rs11801299. It is less likely to have the *MDM4* rs10900598 polymorphism variant GT/TT genotypes for HPV16-positive patients (67.2%) than HPV16-negative patients (77.0%; $P = 0.044$), while HPV16-positive subjects more likely had the rs1380576 CG+GG genotypes than HPV16-negative subjects (57.6% and 45.1%, respectively; $P = 0.017$). Similarly, for the rs11801299 polymorphism, the AG+AA variant genotypes were more likely in HPV16-positive patients (37.6%) than in HPV16-negative patients (25.6%; $P = 0.018$). Such a significant difference was also observed when genotypes were combined; HPV16-positive patients more likely had risk genotypes than HPV16-negative patients (80.6% vs. 61.9%, respectively; $P = 0.003$) (Table 2).

In multivariable analyses after adjusting with age, sex, ethnicity, smoking and alcohol status, a significant difference was noticed for all three polymorphisms. The patients carrying the variant genotypes of *MDM4*rs10900598 had 60% lower risk to have an HPV16-positive tumor than those with the corresponding homozygous genotype (OR, 0.6, 95%CI, 0.4-1.0), while the patients with variant genotypes of *MDM4*rs1380576 (CG+GG) and *MDM4*rs11801299 (AG+AA) were approximately 1.6 and 1.8 folds as likely to be HPV16-positive tumors compared to the cases with their corresponding homozygous genotypes (OR, 1.6, 95%CI, 1.1-2.4 for *MDM4*rs1380576 and OR, 1.8, 95%CI, 1.1-2.9 for *MDM4*rs11801299). Furthermore, after we combined the risk genotypes of the 3 polymorphisms, HPV16-positive SCCOP patients were 2.5 times more likely to have any risk genotypes of the 3 polymorphisms compared with HPV16-negative patients (OR, 2.5, 95% CI, 1.6-3.9) (Table 2).

As shown in Table 3, we further performed stratified analyses by age, sex, ethnicity, and tobacco smoking and

alcohol drinking status to further explore the association between the combined genotypes of three *MDM4* polymorphisms and tumor HPV16 status of SCCOP (Table 3). Among patients under 55 years old, those with any risk genotypes of the 3 polymorphisms were 1.6 times more likely to have a HPV16-positive tumor than those without any variant genotypes (OR, 1.6; 95% CI, 1.0-3.0); however, no significant association was found for patients older than 54 years. Additionally, patients with any risk genotypes of the 3 polymorphisms were more likely to be HPV16-positive SCCOP among non-Hispanic whites (OR, 2.3; 95% CI, 1.4-3.8), and those who were never smokers (OR, 2.3; 95% CI, 1.1-5.0) as well as never alcohol drinkers (OR, 4.6; 95% CI, 1.8-12.2).

DISCUSSION

In the present study, a significant association between the three *MDM4* polymorphisms and HPV16 tumor status in patients with SCCOP were found; and such associations were more pronounced among some subgroups. This result indicates that these *MDM4* genetic variants might have potential to be biomarkers for HPV16-positive tumors of SCCOP, particularly in the patients who were younger, non-smokers, and non-drinkers. To date, this is the first study to explore the association of *MDM4* polymorphisms with tumor HPV16 status in SCCOP.

Identifying reliable predictors of HPV status in SCCOP is clinically useful since tumor HPV status remains the strongest marker for predicting outcome of SCCOP. Our results indicate that the combination of variant genotypes of the 3 *MDM4* variants may be used to serve as more valuable markers for the HPV tumor status of SCCOP. Understanding the tumor HPV16 status of SCCOP may help make treatment decision. Since HPV-positive SCCOP patients have better treatment response and prognoses than HPV-negative SCCOP patients [19], it is likely to help reduce the treatment intensity currently used for HPV-positive SCCOP patients as well as to develop future targeted therapies for such patients. The results from *MDM4* genetic variants could define personalized molecular profiling for future personalized prevention and potentially optimizing patient stratification for HPV16-targeted therapies, leading to better individualized treatment and improved prognosis of SCCOP patients.

Our study demonstrated that some genetic variants of *MDM4* may individually or jointly modify tumor HPV16 status in SCCOP. Although some studies have reported associations of some *MDM4* genetic variants with HPV-associated head and neck cancers [20–24], these studies either defined HPV16 status of study patients by serology or had mixed tumor sites [20, 21, 23, 24]. Although these studies imply that HPV tumor positivity might have favorable prognosis of SCCOP,

Table 2: Risk of SCCOP associated with the *MDM4* genotypes in HPV16+ and HPV16- patients

<i>MDM4</i> genotypes	HPV16+ patients (N =439)		HPV16- patients (N =113)		<i>P</i>	Crude OR (95% CI)	Adjusted OR (95% CI)*
	No.	%	No.	%			
rs10900598					0.044		
GG†	144	32.8	26	23.0		1.0	1.0
GT + TT	295	67.2	87	77.0		0.6 (0.4-1.0)	0.6 (0.4-1.0)
rs1380576					0.017		
CC†	186	42.4	62	54.9		1.0	1.0
CG + GG	253	57.6	51	45.1		1.7 (1.1-2.5)	1.6 (1.1-2.4)
rs11801299					0.018		
GG†	274	62.4	84	74.4		1.0	1.0
AG + AA	165	37.6	29	25.6		1.7 (1.1-2.8)	1.8 (1.1-2.9)
Combined risk genotypes					0.003		
Risk 0	85	19.4	43	38.1		1.0	1.0
Risk 1-3	354	80.6	70	61.9		2.6 (1.6-4.0)	2.5 (1.6-3.9)

P values for χ^2 test for genotype distribution.

*Adjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking status in a logistic regression model.

†Reference group

MDM4 rs10900598 GT/TT, rs1380576 CC, and rs11801299 GG were considered as risk genotypes.

these findings are not in agreement with those from other studies [25–27]. It is likely that some other important factors may also significantly confound the estimates of the associations. Therefore, to ensure future treatment of SCCOP, HPV tumor positivity as a potential biomarker for prognosis requires further validation. The findings from this study indicate that *MDM4* polymorphisms might serve as a biomarker for the HPV16-positive tumors of SCCOP. Since this study included tumor-based HPV16 status and a homogenous subgroup of SCCOP, it might minimize the selection bias on the associations of *MDM4* polymorphisms with tumor HPV16 status of SCCOP.

While how these polymorphisms exactly affect the tumor HPV16 status of SCCOP remains unclear, it is biologically plausible that HPV16 E6 and *MDM4* may jointly affect development of SCCOP by degrading or inhibiting p53. It is biologically that HPV E6 inhibits p53 through proteasomal degradation [28], and *MDM4* directly binds to the p53 transactivation domain for inhibition of p53. Thus, the overexpression of *MDM4* could inhibit the p53 activity, and functionally affect p53-dependent pathway, thus affecting several p53-related cellular activities. This altered regulation may affect the interaction of p53 with HPV16 through degradation or inactivation of HPV16 E6 oncoprotein [16], thus could suppressing cell growth and inducing apoptosis. It is likely

that *MDM4* variants could jointly modify association with tumor HPV16 status in SCCOP by interaction with HPV16 E6 and p53.

It is well known that patients with HPV16-positive SCCOP tended to be likely non-smokers or non-drinkers. Indeed, our findings from stratification analysis have demonstrated that modifying effect of combined *MDM4* risk genotypes on SCCOP tumor HPV16 positivity was much higher in never-smokers and never-drinkers. Such a finding could additionally support those results from previously reported work. In these studies, they demonstrated that HPV infection may cause a significant portion of SCCOP, whereas smoking and drinking induced the majority of non-SCCOP [29, 30]. Since HPVs can bypass immune systems, and *MDM4* polymorphisms can modulate the apoptotic capacity through p53 pathway, both molecular pathways eventually controlling the HPV clearance through escape of immune surveillance, subsequently affecting the tumor HPV status [31]. Additionally, the association of tumor HPV16 status with combined *MDM4* risk genotypes in SCCOP was more evident among ever-drinkers in the current study, implying HPV16 could interact with alcohol and smoking, even though non-drinkers more likely had HPV-positive tumors than ever-drinkers [32]. Furthermore, smokers or alcohol drinkers may synergize with *MDM4* polymorphisms

Table 3: Stratification analysis of *MDM4* genotypes, OR, and 95% CIs by selected variables

Variable	HPV16 ⁺ patients (N =439)				HPV16 ⁻ patients (N =113)				Adjusted OR (95%CI)*	
	No risk		With 1-3 risk		No risk		With 1-3 risk		No variants [†]	With variants
	No.	%	No.	%	No.	%	No.	%		
All subjects	85	19.4	354	80.6	43	38.1	70	61.9	1.0	2.5 (1.6-3.9)
Age										
≤54 years	50	22.2	175	77.8	18	30.5	41	69.5	1.0	1.6 (1.0-3.0)
>54 years	35	16.4	179	83.6	25	46.3	29	53.7	1.0	1.9 (0.9-2.7)
Sex										
Male	75	19.5	309	80.5	32	37.6	53	62.4	1.0	2.8 (1.4-3.9)
Female	10	18.2	45	81.8	11	39.3	17	60.7	1.0	3.1(1.1-9.2)
Ethnicity										
Non-Hispanic White	79	19.6	325	80.5	37	37.4	62	62.6	1.0	2.3 (1.4-3.8)
Others	6	17.1	29	82.9	6	42.9	8	57.1	1.0	4.6 (0.9-21.7)
Smoking status										
Ever	51	20.2	201	79.8	29	38.7	46	61.3	1.0	1.6 (0.7-3.5)
Never	34	18.2	153	81.8	13	35.1	24	64.9	1.0	2.3 (1.1-5.0)
Drinking status										
Ever	66	19.9	265	80.1	30	34.1	58	65.9	1.0	2.0 (0.9-4.0)
Never	19	17.6	89	82.4	12	50.0	12	50.0	1.0	4.6 (1.8-12.2)

*Adjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking status in a logistic regression model.

[†]Reference group.

to affect HPV16 status through suppression of immune systems, clearing the HPV-infected cells and thus less likely to be tumor HPV16-positive SCCOP. Nevertheless, these findings need to be further validated in future studies with large sample sizes.

In interpretation of our findings some limitations should be taken into account. Several strengths from this study are: 1) inclusion of single SCCOP tumor site only; 2) use of HPV16 tumor status rather than serology; and 3) good quality control for genotyping. Our these strengths may help minimize the confounding issues from mixed tumor sites, and serological HPV16 status and significantly increase accuracy of the association in this study. Despite of such several strengths, our study also have several limitations. These include 1) no frequency matching on different demographic, epidemiological, and clinical characteristics between HPV16-positive

and HPV16-negative cancer patients in this study; 2) inclusion of small sample sizes and a possible selection bias; 3) potential misclassification of tumor HPV16 status due to limitation of current HPV determination methods; and 4) not possible representation of true prevalence of HPV 16 exposure in the general population when tumor HPV16-negative patients as comparison controls. Thus, prospective, larger or multi-center studies are required to validate our findings in the future.

In conclusion, our present study provides evidence for the first time that three *MDM4* gene polymorphisms could significantly modify individually or in combination the tumor HPV status in SCCOP. *MDM4* genetic variants could be biomarkers for predicting tumor HPV16-positivity of patients with SCCOP, particularly in never-smokers and never-drinkers SCCOP patients. However, validation of these results in larger studies are needed.

MATERIALS AND METHODS

Study subjects

A total of 552 incident patients with SCCOP were diagnosed and treated from December 1996 to July 2011 at The University of Texas (U.T.) M. D. Anderson Cancer Center were consecutively recruited. The criteria of inclusion and exclusion were described previously [14]. The study was approved by the Institutional Review Boards of U. T. M.D. Anderson Cancer Center, and all study participants signed informed consent for the sample analysis of genetic variation. All enrolled patients donated 30 ml of blood for genotyping. Paraffin-embedded tumor tissue samples were assessed for HPV16 status. Ever-smokers were defined as patients who had smoked over 100 cigarettes during their lifetimes and otherwise as never-smokers. Drinking status was classified as “ever-drinkers” (alcoholic beverage at least once a week for 1 year) and “never-drinkers” (never had such a drinking pattern).

MDM4 polymorphism selection/genotyping and HPV16 detection

To select *MDM4* polymorphisms for this study, we used the public HapMap SNP database to identify the tagging SNPs, as we previously reported¹⁹. All selected SNPs either were directly genotyped or exceeded a threshold level of linkage disequilibrium (LD) value (r^2) with a genotyped SNP within an about 34-kb region of *MDM4* gene among a European population. These tagging SNPs were selected according to their pairwise LD with the r^2 threshold of 0.8 and minor allele frequency (MAF) ≥ 0.10 . Thus, three tagging SNPs were identified including rs11801299, rs1380576, and rs10900598, in the 34-kb region, and the mean r^2 between the tagging SNPs and their covered but untyped SNPs was 0.98¹⁹. For the 3 polymorphisms, *MDM4*rs11801299 and *MDM4*rs10900598 are within the 3' UTR; and *MDM4*rs1380576 is located in the intron 1 of the *MDM4* gene. Genomic DNA before treatment was extracted from blood samples for *MDM4* genotyping. The detail of these methods have been previously described [18, 33]. The paraffin-embedded tissues were used for HPV16 status detection as described previously [5, 24]. For quality control, 10% of samples were retested to verify genotyping and 5% of the tissues samples were retested for tumor HPV16 status. The results of these repeated samples were 100% concordant.

Statistical analysis

Differences in demographic characteristics, smoking and drinking status, and *MDM4* genotypes between HPV16-positive and HPV16-negative patients were

detected using χ^2 test. Both univariate and multivariable logistic regression analyses were used to estimate the association between *MDM4* genotypes and tumor HPV16 positivity among SCCOP by computing the odds ratios (ORs) and 95% confidence intervals (CIs). The genotype data were further analyzed by stratifying into subgroups by age, sex, ethnicity, smoking and drinking status in multivariable logistic regression models. Statistical Analysis System software (Version 9.3; SAS Institute, Cary, NC) was used to perform all of the statistical analyses. All tests were two-sided, and a *P* value of 0.05 was considered significant.

Abbreviations

MDM4: Mouse double minute 4; HPV: human papillomavirus; SCCOP: squamous cell carcinoma of oropharynx; SNPs: single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; SCCHN: SCC of head and neck.

Author contributions

ZL, HZ conceived the study, YT participated in its design and coordination. ZL and GL performed the statistical analysis. ZL carried out the experiments and drafted the manuscript. XL and GL performed a critical revision of the manuscript. The overall study was supervised by XL and GL. All authors revised the manuscript critically and approved the final manuscript.

ACKNOWLEDGMENTS

The authors thank Margaret Lung, Kathryn L. Tipton, Liliana Mugartegui, and Angeli Fairly for their help with participant recruitment and Li-E Wang for laboratory management.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING SUPPORT

This work was supported by start-up funds from The University of Texas MD Anderson Cancer Center (to E.M.S.), a National Institutes of Health Head and Neck Specialized Program of Research Excellence Career Development Award (P50CA097007 to E.M.S.), an Institutional Research Grant from The University of Texas MD Anderson Cancer Center (to E.M.S.), and other National Institutes of Health grants: grants ES011740 and CA131274 (to Q.W.), a Clinician Investigator Award (K12CA88084 to E.M.S.), a Cancer Center Support Grant to The University of Texas MD Anderson Cancer Center

(CA16672), and grants CA135679, CA133099, and 1R03CA186261-01A1 (to G.L.).

REFERENCES

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Ehemann C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. *J Nat Cancer Inst.* 2013; 105: 175-201.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol.* 2011; 29: 4294-4301.
3. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol.* 2013; 31: 4550-4559.
4. Stein AP, Saha S, Yu M, Kimple RJ, Lambert PF. Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. *Chem Res Toxicol.* 2014; 27: 462-469.
5. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin Oncol.* 2015; 33: 3235-3242.
6. Castellsague X, Alemany L, Quer M, Holec G, Quiros B, Tous S, Clavero O, Alos L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. *J Nat Cancer Inst.* 2016; 108: djv403.
7. Okami K. Clinical features and treatment strategy for HPV-related oropharyngeal cancer. *Int J Clin Oncol.* 2016; 21: 827-835.
8. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, et al. Comprehensive control of human papillomavirus infections and related diseases. *Vaccine.* 2013; 31: H1-31.
9. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Eng J Med.* 2010; 363: 24-35.
10. Bhatia A, Burtness B. Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. *J Clin Oncol.* 2015; 33: 3243-3250.
11. Lane DP. Cancer. p53, guardian of the genome. *Nature.* 1992; 358: 15-16.
12. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. *Hum Pathol.* 2007; 38: 1553-1562.
13. Karni-Schmidt O, Lokshin M, Prives C. The Roles of MDM2 and MDMX in Cancer. *Annu Rev Pathol.* 2016; 11: 617-644.
14. Wang Z, Sturgis EM, Zhang Y, Huang Z, Zhou Q, Wei Q, Li G. Combined p53-related genetic variants together with HPV infection increase oral cancer risk. *Int J Cancer.* 2012; 131: E251-258.
15. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. *Virus Res.* 2002; 89: 213-228.
16. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell.* 1993; 75: 495-505.
17. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. *J Clin Oncol.* 2006; 24: 2606-2611.
18. Yu H, Sturgis EM, Liu Z, Wang LE, Wei Q, Li G. Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynx. *Cancer.* 2012; 118: 1684-1692.
19. Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. *J Cell Biochem.* 2016; 117: 2682-2692.
20. Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, Wei Q, Li G. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. *Carcinogenesis.* 2008; 29: 875-879.
21. Chen X, Sturgis EM, Etzel CJ, Wei Q, Li G. p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. *Cancer.* 2008; 113: 3307-3314.
22. Perrone F, Mariani L, Pastore E, Orsenigo M, Suardi S, Marcomini B, DaRiva L, Licitra L, Carbone A, Pierotti MA, Pilotti S. p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. *Cancer.* 2007; 109: 2461-2465.
23. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. *Carcinogenesis.* 2008; 29: 2120-2125.
24. Ji X, Sturgis EM, Zhao C, Etzel CJ, Wei Q, Li G. Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell

- carcinoma of the head and neck in non-Hispanic whites. *Cancer*. 2009; 115: 1660-1668.
25. Pintos J, Franco EL, Black MJ, Bergeron J, Arella M. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. *Cancer*. 1999; 85: 1903-1909.
 26. Baez A, Almodovar JI, Cantor A, Celestin F, Cruz-Cruz L, Fonseca S, Trinidad-Pinedo J, Vega W. High frequency of HPV16-associated head and neck squamous cell carcinoma in the Puerto Rican population. *Head Neck*. 2004; 26: 778-784.
 27. Koskinen WJ, Chen RW, Leivo I, Makitie A, Back L, Kontio R, Suuronen R, Lindqvist C, Auvinen E, Molijn A, Quint WG, Vaheeri A, Aaltonen LM. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. *Int J Cancer*. 2003; 107: 401-406.
 28. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. *Oncogene*. 1999; 18: 7690-7700.
 29. Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK, Spitz MR, Schiller JT, Wei Q, Sturgis EM. Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. *Clin Cancer Res*. 2003; 9: 2620-2626.
 30. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T, Munck-Wikland E. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. *Int J Cancer*. 2006; 119: 2620-2623.
 31. Favre A, Paoli D, Poletti M, Marzoli A, Pesce G, Giampalmo A, Rossi F. The human palatine tonsil studied from surgical specimens at all ages and in various pathological conditions. 1. Morphological and structural analyses. *Z Mikrosk Anat Forsch*. 1986; 100: 7-33.
 32. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. *Arch Otolaryngol Head Neck Surg*. 1997; 123: 513-516.
 33. Yu H, Wang LE, Liu Z, Wei S, Li G, Sturgis EM, Wei Q. Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. *Pharmacogenet Genomics*. 2011; 21: 388-396.